Information Provided By:
Fly News Breaks for December 23, 2019
Dec 23, 2019 | 08:14 EDT
Baird analyst Brian Skorney is positive on Roche (RHHBY) deal for ex-U.S. and expects Sarepta's (SRPT) shares to trade at all-time highs off the news, but believes still more value remains in addressing DMD. The analyst also believes the deal clears out numerous points of pushback as he believes the validation from a big pharma mega-deal should dampen any concerns around safety, manufacturing capability, or financing risk. This effectively puts Sarepta in a position to complete the pivotal program for SRP-9001, build substantial commercial supply, and launch SRP-9001, which should turn Sarepta profitable in the first quarter or two of launch, he adds.
News For SRPT;RHHBY From the Last 2 Days
There are no results for your query SRPT;RHHBY